Cargando…

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botticelli, Andrea, Fabbri, Agnese, Roberto, Michela, Alesini, Daniele, Cirillo, Alessio, D’Auria, Giuliana, Krasniqi, Eriseld, Marrucci, Eleonora, Muratore, Margherita, Pantano, Francesco, Pizzuti, Laura, Portarena, Ilaria, Rossi, Rosalina, Scagnoli, Simone, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864134/ https://www.ncbi.nlm.nih.gov/pubmed/35223478 http://dx.doi.org/10.3389/fonc.2022.797157

Ejemplares similares

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
por: Fabbri, Agnese, et al.
Publicado: (2023)

Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study
por: Nelli, Fabrizio, et al.
Publicado: (2023)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
por: Cirillo, Alessio, et al.
Publicado: (2023)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2017)

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
por: Loke, Lydia, et al.
Publicado: (2020)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
por: Vici, Patrizia, et al.
Publicado: (2021)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
por: Pizzuti, Laura, et al.
Publicado: (2020)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
por: James, Alexander D., et al.
Publicado: (2020)

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Emerging role of S-1 in gastric cancer
por: Krasniqi, Eriseld, et al.
Publicado: (2015)

Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer
por: Makino, Tomoyuki, et al.
Publicado: (2021)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
por: Botticelli, Andrea, et al.
Publicado: (2020)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
por: Fasching, Peter A., et al.
Publicado: (2020)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uso4iiq73o4fji6pfj2g2il96m